MMR vaccine - Berna BiotechAlternative Names: Measles-mumps-rubella-vaccine-Berna Biotech
Latest Information Update: 03 Jun 2010
At a glance
- Originator Berna Biotech
- Class Measles vaccines; Rubella vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Measles; Mumps; Rubella
Most Recent Events
- 30 Nov 2003 Phase-III clinical trials in Rubella in Switzerland (Injection)
- 30 Nov 2003 Phase-III clinical trials in Mumps in Switzerland (Injection)
- 30 Nov 2003 Phase-III clinical trials in Measles in Switzerland (Injection)